Danbury-based Biodel Inc., a biopharmaceutical company, has been selected for inclusion in the Nasdaq Biotechnology Index, effective as of the market’s open on Monday, May 19.
“We are pleased to be included in the Nasdaq Biotechnology Index and believe Biodel’s inclusion is a result of the company’s consistent achievement of its goals,” Dr. Solomon Steiner, chairman and CEO of Biodel, said in a statement. “We look forward to reporting on future 2008 goals.”
